Presenters
Course Details
The triad of hypertension, diabetes and chronic kidney disease (CKD) are all inter-related and may complicate the treatment of hypertension. In this webinar in partnership with the Philippine Society of Nephrology, Philippine Academy of Family Physicians, and Diabetes Philippines, Dr. Romeo Santos (Our Lady of Lourdes Hospital) spoke about the principles of management of hypertension in patients with the said triad. He was then joined by Dr. Elizabeth Roasa (University of Santo Tomas) and Dr. Grace delos Santos in a lively panel discussion. The webinar was moderated by Dr. Mighty Ramirez (University of Santo Tomas).
About the speakers
Dr. Romeo Santos is the Head of Cardiology and Heart Station Department of the Our Lady of Lourdes Hospital and is a Past President of the Philippine Heart Association.
Dr. Elizabeth Roasa is Professor 1 at the Faculty of Medicine and Surgery of the University of Santo Tomas and is a Past President of the Philippine Society of Nephrology.
Dr. Grace delos Santos is the Chief of Clinics and Director of Medical Education of Metropolitan Medical Center and is a Past President of Diabetes Philippines and the Philippines Society of Diabetologists.
Dr. Marcellus Francis “Mighty” Ramirez is Assistant Professor at the UST Faculty of Medicine and Surgery and heads the Arrhythmia and Electrophysiology Services and Pacemaker Clinic of UST Hospital.
Estimated time of Completion: 1 hr. 28 mins. 12 sec.
CPD Points: 1.5 Points
PRC Program No: PROG-2022-40190
Meet the masters: Management of hypertension in patients with diabetes and CKD Course Outline
Romeo J. Santos, MD, FPCP, FPCC, FPSE, FACC
- Learning objectives
- Definition of Diabetes with Chronic Kidney Disease
- Diabetes with Chronic Kidney Disease
- Burden of Diabetes with Chronic Kidney Disease
- PRESYON 4
- PRESYON 4: Hypertension and diabetes
- PRESYON 4: Hypertension and microalbuminuria
- Diabetes and is complications
- Mechanisms of Vascular Complications in Diabetes and the Impact of Hypertension
- How Diabetes and Hypertension lead to Chronic Kidney Disease
- Prevalence of cardiovascular disease in people with normal kidney function and patients with chronic kidney disease. USA Data 2018
- What do the Latest Evidence and Guidelines Say?
- American Heart Association and European Society of Cardiology
- + International Society of Hypertension
- 2020 ISH Simplified Classification of Hypertension Risk
- Initiation of Treatment for Hypertension
- Treatment strategies in people with diabetes
- ASN recommendations for Diabetes with CKD (BP-lowering therapy)
- ASN recommendations for Diabetes with CKD (glucose-lowering)
- 2020 Philippine Hypertension CPG
- CKD-specific recommendations for HPN
- Pharmacological Profile of Telmisartan
- ONTARGET: Telmisartan as Effective as Ramipril in Preventing CV Events at Increased CV Risk
- Telmisartan versus Ramipril in renal ENdothelial DYsfunction study
- Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study
- telMisartan (80mg) vs. losArtan (100mg) in hypertensive type-2 DiabEtic patients with Overt nephropathy
- Telmisartan reduced transition from incipient to overt nephropathy and induced remission of albuminuria in Japanese type 2 diabetes patients (INNOVATION study)
- Telmisartan is efficient along the renal continuum
- Asian Pacific Society of Nephrology (ASN) Model of Care for patients with Diabetes with Chronic Kidney Disease
- Comprehensive Care in Patients with Diabetes and CKD
- Empagliflozin Significantly Reduced the Relative Risk of Incident or Worsening Nephropathy by 39% on Top of Standard Care
- Empagliflozin Reduced the Relative Risk of Progression to Macroalbuminuria by 38% on Top of Standard of Care
- High-risk Patients: Advantage of RAAS inhibitors
- Summary
Panel discussion & Q&A on hypertension & patients with diabetes and CKD with Dr. Grace delos Santos, Dr. Elizabeth Roasa, Dr. Romeo Santos, and Dr. Marcellus Ramirez.
PC-PH-103171 / September 2023